Investing.com - Financial Markets Worldwide

Scopus Biopharma Inc (SCPS)

OTC Markets
Currency in USD
0.010
0.000(0.00%)
Closed·
SCPS Scorecard
Full Analysis
Stock generally trades with high price volatility
Trading near 52-week High
SCPS is not included in our AI-picked strategies. See which stocks are.
Fair Value
Unlock Value
Day's Range
0.0100.010
52 wk Range
0.0010.010
Key Statistics
Edit
Prev. Close
-
Open
0.01
Day's Range
0.01-0.01
52 wk Range
0.001-0.01
Volume
-
Average Volume (3m)
10.92K
1-Year Change
400%
Book Value / Share
-
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
SCPS Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Technical Analysis
Strong Buy
Analysts Sentiment
Currently not supported.
Members' Sentiments
Bearish
Bullish
ProTips
Unlock All 7
Suffers from weak gross profit margins
Unlock InvestingPro

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Buy
Technical Indicators
Buy
Moving Averages
Buy

Scopus Biopharma Inc Company Profile

Scopus BioPharma Inc., a clinical-stage biopharmaceutical company, focuses on developing transformational therapeutics targeting serious diseases with unmet medical needs. It offers Duet Platform, which consists of signal transducer and activator of transcription 3 (STAT3), a master immune checkpoint inhibitor and toll-like receptor 9 (TLR9), as well as includes CpG-STAT3ASO (DUET-02), CpG-STAT3siRNA (DUET-01), and CpG-STAT3decoy (DUET-03); and that develops a suite of bifunctional oligonucleotides that activate antigen-presenting cells (APCs) in the tumor microenvironment that alleviates tumor immunosuppression to jump-start T cell-mediated immune responses. The company is also developing DUET-01, as a monotherapy targeting B-cell non-Hodgkin lymphoma; DUET-02 that provides systemic delivery for treatment of solid tumors comprising prostate or kidney cancers; and DUET-03, which targets the actual STAT3 transcription factor protein. Scopus BioPharma Inc. has licensing agreements with the City of Hope, National Institutes of Health Program, and The Hebrew University of Jerusalem. The company was formerly known as Project18 Inc. and changed its name to Scopus BioPharma Inc. in December 2017. Scopus BioPharma Inc. was incorporated in 2017 and is headquartered in New York, New York.

Industry
Biotechnology & Medical Research
Sector
Healthcare
Employees
13
Market
United States

Compare SCPS to Peers and Sector

Metrics to compare
SCPS
Peers
Sector
Relationship
P/E Ratio
0.0x−3.1x−0.5x
PEG Ratio
0.00−0.060.00
Price/Book
0.0x2.2x2.6x
Price / LTM Sales
0.0x8.7x3.3x
Upside (Analyst Target)
0.0%209.7%41.6%
Fair Value Upside
Unlock5.1%5.9%Unlock

Earnings

Latest Release
May 28, 2025
EPS / Forecast
-- / --
Revenue / Forecast
-- / --
EPS Revisions
a
a
Unlock
Last 90 days

SCPS Income Statement

FAQ

What Stock Exchange Does Scopus Trade On?

Scopus is listed and trades on the OTC Markets stock exchange.

What Is the Stock Symbol for Scopus?

The stock symbol for Scopus is "SCPS."

What Is the Scopus Market Cap?

As of today, Scopus market cap is 420.84K.

What Is Scopus's Earnings Per Share (TTM)?

The Scopus EPS (TTM) is -0.31.

When Is the Next Scopus Earnings Date?

Scopus will release its next earnings report on 02 Sept 2025.

From a Technical Analysis Perspective, Is SCPS a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Scopus Stock Split?

Scopus has split 0 times.

How Many Employees Does Scopus Have?

Scopus has 13 employees.

What is the current trading status of Scopus (SCPS)?

As of 13 Aug 2025, Scopus (SCPS) is trading at a price of 0.01, with a previous close of 0.00. The stock has fluctuated within a day range of 0.01 to 0.01, while its 52-week range spans from 0.00 to 0.01.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.